Filtered By:
Condition: Atrial Fibrillation
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 1248 results found since Jan 2013.

Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants
We report a case of an ischemic stroke after a successful catheter ablation of atrial fibrillation (AF) and continuous oral anticoagulation therapy with direct oral anticoagulants (DOACs), which was the trigger for diagnosing antiphospholipid syndrome (APS). A 68-year-old woman underwent catheter ablation of persistent AF and continued oral anticoagulation with edoxaban at a dose of 30 mg once daily after the ablation procedure. An asymptomatic intracerebral hemorrhage was detected by brain computed tomography and magnetic resonance imaging one month post-ablation. Oral anticoagulation with dabigatran at 110 mg twice daily...
Source: International Heart Journal - January 31, 2022 Category: Cardiology Authors: Yumiko Haraguchi Kohki Nakamura Mitsuho Inoue Takehito Sasaki Kentaro Minami Shingo Yoshimura Shigeto Naito Source Type: research

Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
ConclusionBased on current evidence, for stroke prevention and treatment in patients with AF, the most safe DOAC is edoxaban in terms of fatal bleeding; dabigatran in terms of major bleeding and intracranial hemorrhage and apixaban in terms of gastrointestinal bleeding. However, given the nature of indirect comparisons, more high-quality evidence from head-to-head comparisons is still needed to confirm them.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research

NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: Evidence > Guidelines NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:   . prior stroke or transient ischaemic attack . age 75 years or older . hypertension . diabetes mellitus . symptomatic heart failure.   NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

Abstract 200: Cost-Effectiveness of Newer Anticoagulants for Stroke Prevention in Atrial Fibrillation Poster Session II
Conclusions: Cost-effectiveness models of newer anticoagulants for SPAF have been extensively published. Models have frequently found newer anticoagulants to be cost-effective, but due to the lack of head-to-head trial comparisons and heterogeneity in clinical characteristic of underlying trials and modeling methods, it is currently unclear which of these newer agents is most cost-effective.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Limone, B. L., Baker, W. L., Coleman, C. I. Tags: Poster Session II Source Type: research

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
Conclusion: SD-W has the lowest C/U ratio among the 3 options. However, dabigatran might be considered as an alternative. GT-W is not C/U and should not currently be recommended for the routine anticoagulotherapy management of AF patients.
Source: Thrombosis Journal - July 17, 2013 Category: Hematology Authors: Léon NshimyumukizaJulie DuplantieMathieu GagnonXavier DouvilleDiane FournierCarmen LindsayMarc ParentAlain MilotYves GiguèreChristian GagnéFrançois RousseauDaniel Reinharz Source Type: research

New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an are...
Source: Neurologic Clinics - July 31, 2013 Category: Neurology Authors: Maria I. Aguilar, Ruth S. Kuo, William D. Freeman Source Type: research

Remember to weigh up risks and benefits of new PBS-listed anticoagulants
NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 - and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose. These medicines will be subsidised by the Pharmaceutical Benefits Scheme (PBS) for preventing stroke in people with non-valvular atrial fibrillation, and may offer alternatives for some people...
Source: Health News from Medical News Today - September 4, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an are...
Source: Neurologic Clinics - August 1, 2013 Category: Neurology Authors: Maria I. Aguilar, Ruth S. Kuo, William D. Freeman Source Type: research

Maybe Pradaxa (dabigatran) does need blood monitoring after all
2.5 out of 5 stars The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. Reilly PA et al. J Am Coll Cardiol 2014 Feb 4;63:321-8. Abstract A must-read article in yesterday’s New York Times described the internal battle at Boehringer Ingelheim, the maker of Pradaxa (dabiagtran etexilate), concerning the publication of this study. A major marketing point posited in favor of dabigatran over warfarin for the prevention of stroke in patients with atrial fibrillation was that it did not require monitoring with reg...
Source: The Poison Review - February 7, 2014 Category: Toxicology Authors: Leon Tags: Medical bleeding blood testing boehringer ingelheim dabigatran pradaxa stroke Source Type: news

New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Abstract Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation in their respective trials. The first three have been approved, while edoxaban is awaiting regulatory approval. Several guidelines have endorsed the approved new oral anticoagulants over warfarin because of their favourable risk-benefit ratio, low propensity for food and drug interactions, and lack of requirement for routine coagulation monitoring. In this invited review, we summarise ...
Source: Thrombosis and Haemostasis - February 20, 2014 Category: Hematology Authors: Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS Tags: Thromb Haemost Source Type: research

Meta-Analysis of Risk of Stroke or Transient Ischemic Attack With Dabigatran for Atrial Fibrillation Ablation
In conclusion, periprocedural use of dabigatran for AF ablation was related to a higher risk of thromboembolic complications including stroke and transient ischemic attack.
Source: The American Journal of Cardiology - January 16, 2014 Category: Cardiology Authors: Partha Sardar, Ramez Nairooz, Saurav Chatterjee, Jørn Wetterslev, Joydeep Ghosh, Wilbert S. Aronow Tags: Arrhythmias and Conduction Disturbances Source Type: research

Dabigatran Etexilate for Secondary Stroke PreventionDabigatran Etexilate for Secondary Stroke Prevention
While dabigatran has proven effective for reducing stroke risk in patients with nonvalvular atrial fibrillation, there is growing concern regarding potential adverse effects. What are the risks? Therapeutic Advances in Neurological Disorders
Source: Medscape Today Headlines - June 13, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study
This study revealed, that in clinical practice, vitamin K antagonist-experienced patients with a history of stroke or transient ischemic attack who switch to dabigatran therapy may have an increased rate of a recurrent stroke compared to patients persisting with vitamin K antagonist therapy.
Source: The American Journal of Medicine - September 1, 2014 Category: Journals (General) Authors: Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, Anders Gorst-Rasmussen, Flemming Skjøth, Deirdre A. Lane, Gregory Y.H. Lip Source Type: research

Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
Conclusion Rivaroxaban may be a cost-effective alternative to warfarin for the prevention of stroke in patients with AF in Singapore.
Source: Cardiovascular Drugs and Therapy - October 16, 2014 Category: Cardiology Source Type: research